{
  "abstract": "Alzheimer’s disease (AD), as a chronic neurodegenerative disorder, leads to progressive dementia. About 60–80% of dementia cases are due to AD, and their incidence increases especially after the age of 65. AD is characterized by impaired memory, abnormal behavior, and impaired thinking process, which causes limitation of daily activities and a gradual loss of independence. The costs of all dementia cases are likely to reach $2 trillion in 2030 alone. Currently available pharmacological treatment of AD is, for the most part, not causal, and does not modify the course of the disease. The data search for procognitive drugs was carried out using the PUBMED and Clinical Science databases. Among the drugs with animal data and preliminary clinical trials, the following can be distinguished: fosgonimeton, blarcamesine, bezisterim, posiphen (buntanetap) and ACD856. As a rule, promising preclinical results were not confirmed in clinical trials. Some clinical expectations may be associated with posiphen and ACD856. Based on preclinical data, the following drugs seem promising: tenuigenin, JQ1, gemfibrozil, coumarin derivatives, ponicidin, salicin, calcaratarin D, new 1,3,5-triazines or 2-aminopyrymidine carboxamide derivatives, epimedium brevicornu flavonoids, and drugs affecting the glymphatic system. In general, the above-mentioned drugs counteract the pathologies leading to the occurrence of AD.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Pathophysiology, Medical University of Lublin, 20-090 Lublin, Poland"
  ],
  "article_type": null,
  "arxiv": null,
  "author_total": 3,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Barbara Miziak"
    },
    {
      "affs": [
        0
      ],
      "name": "Ryszard Pluta",
      "orcid": "0000-0003-0764-1356"
    },
    {
      "affs": [
        0
      ],
      "name": "Stanisław J. Czuczwar"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/995vef8srfj0s.bib",
  "cited_by": 0,
  "doi": "10.3390/ijms27219959",
  "fulltext_url": null,
  "id": "995vef8srfj0s",
  "issns": [
    "1422-0067"
  ],
  "landing_url": "https://www.mdpi.com/1422-0067/27/21/9959",
  "language": null,
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [],
  "openalex": null,
  "pdf_url": null,
  "pmcid": null,
  "pmid": null,
  "published": "2026-11-06",
  "publisher": "MDPI AG",
  "ris": "https://research.draconitic.com/paper/995vef8srfj0s.ris",
  "sources": [
    {
      "first_seen": "2026-11-10T00:21:27Z",
      "native_id": "10.3390/ijms27219959",
      "source": "crossref",
      "url": "https://www.mdpi.com/1422-0067/27/21/9959"
    }
  ],
  "subjects": [
    {
      "field": "biochemistry",
      "origin": "issn:1422-0067",
      "subfield": "general"
    }
  ],
  "title": "Current Possible Newer Pharmacological Treatment Options for Alzheimer’s Disease",
  "title_text": "Current Possible Newer Pharmacological Treatment Options for Alzheimer’s Disease",
  "type": "peer-reviewed",
  "updated_at": "2026-11-10T00:21:27Z",
  "url": "https://research.draconitic.com/paper/995vef8srfj0s",
  "venue": "International Journal of Molecular Sciences",
  "versions": []
}